Ben-DovI.Z., GalitzerH., Lavi-MoshayoffV.. The parathyroid is a target organ for FGF23 in rats.J Clin Invest2007; 117(12): 4003–8.
2.
Kuro-oM., MatsumuraY., AizawaH.. Mutation of the mouse klotho gene leads to a syndrome resembling ageing.Nature1997; 390(6655): 45–51.
3.
GutierrezO.M., MannstadtM., IsakovaT.. Fibroblast Growth Factor 23 an mortality among patients undergoing hemodialysis.N Engl J Med2008; 359: 584–92.
4.
HolickM.F.Vitamin D deficiency.N Engl J Med2007; 357: 266–81.
5.
JeanG., TerratJ.C., VanelT.. High levels of serum fibroblast growth factors (FGF)-23 are associated with increased mortality in long haemodialysis patients.Nephrol Dial Transplant2008; 23: 3670–6.
6.
CourbebaisseM.. Effects of vitamin D supplementation on the calcium-phosphate balance in renal transplant patients.Kidney Int2009; 75: 646–51.
7.
SeilerS., HeineG.H., FliserD.Clinical relevance of FGF-23 in chronic kidney disease.Kidney Int2009; 76(Suppl 114): S34–42.
8.
NishidaY., TaketaniY., Yamanaka-OkumuraH.. Acute effect of oral phosphate loading on serum fibroblast growth factor 23 levels in healthy men.Kidney Int2006; 70: 2141–7.
9.
GutierrezO., IsakovaT., RheeE.. Fibroblastic growth factor 23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease.J Am Soc Nephrol2005; 16: 2205–15.
10.
BerndtT., ThomasL.F., CraigT.. Evidence for a signaling axis by which intestinal phosphate rapidly modulates renal phosphate reabsorption.Proc Nat Acad Sci USA2007; 104: 11085–90.
11.
SanchezC.M., BajoM.A., SelgasR.. Parathormone Secretion in Peritoneal Dialysis Patients With Adynamic Bone Disease.Am J Kidney Dis2000; 36: 953.
12.
AndressD.L.Adynamic bone in patients with chronic kidney disease.Kidney Int2008; 73: 1345–54.
13.
LondonG.M., MartyC., MarchaisS.J.. Arterial calcifications and bone histomorphometry in end-stage renal disease.J Am Soc Nephrol2004; 15: 1943–51.
14.
MorroneL.F., MazzaferroS., RussoD.. Interaction between parathyroid hormone and the Charlson comorbidity index on survival of incident haemodialysis patients.Nephrol Dial Transplant2009; 24: 2859–65.
15.
CoenG.. Renal Osteodystrophy in Predialysis and Hemodialysis Patients: Comparison of Histologic Patterns and Diagnostic Predictivity of Intact PTH.Nephron2002; 91: 103–11.
16.
CoenG., ManniM., MantellaD.. Are PTH serum levels predictive of coronary calcifications in haemodialysis patients?Nephrol Dial Transplant2007; 22: 3262–7.
17.
YoungE.W., AlbertJ.M., SatayathumS.. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study.Kidney Int2005; 67: 1179–87.
18.
MelamedML, EustaceJ.A., PlantingaL.. Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study.Kidney Int2006; 70: 351–7.
19.
TentoriF., BlayneyM.J., AlbertJ.M.. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: The Dialysis Outcomes and Practice Patterns Study (DOPPS).Am J Kidney Dis2008; 52: 519–30.
20.
HarisA., SherrardD.J., HerczG.Reversal of adynamic bone disease by lowering of dialysate calcium.Kidney Int2006; 70: 921–7.
21.
DaneseMD, BelozeroffV., SmirnakisK., RothmanK.J.Consistent control of mineral and bone disorder in incident hemodialysis patients.Clin J Am Soc Nephrol2008; 3: 1423–9.
